- Recursion Pharmaceuticals reported Q3 2026 revenue of US$18.55 million and a net loss of US$119.04 million, alongside fresh Phase 2 data for REC-4881 in familial adenomatous polyposis and the appointment of industry veteran Fred Hassan as Chair of the Board.
- The combination of REC-4881’s positive polyp burden data and Hassan’s deep large pharma background increases attention on how Recursion’s AI-first platform might translate into later stage assets and potential commercial pathways over time.
- The focus now turns to how Recursion Pharmaceuticals’ investment narrative may evolve in light of REC-4881’s Phase 2 readout and upcoming registrational plans.
Recursion Pharmaceuticals Investment Narrative Recap
To own Recursion Pharmaceuticals, you need to believe its AI driven discovery engine and clinical platform can turn candidates like REC 4881 into real products and more lucrative partnerships while keeping spending under control. The latest quarter showed US$18.55 million in revenue and a net loss of US$119.04 million, so this is still a funding heavy story.
The main near term swing factor remains clinical and partnering momentum relative to cash burn, not single quarter revenue. Q3 results showed a narrower loss than a year ago, which supports the spending narrative but does not resolve the key risk that ongoing losses and past dilution could force more capital raises if milestones or late stage progress slow.
The REC 4881 Phase 2 update is the announcement that matters most for the current catalyst set. Data showing broad reductions in polyp burden with a generally manageable safety profile gives Recursion Pharmaceuticals a clearer path toward a planned registrational trial, subject to FDA discussions, and offers a more concrete test case for the AI platform.
For you as an investor, that trial plan sharpens both opportunity and execution risk. A successful registrational program could help validate Recursion’s model of pairing AI discovery with in house development, while any setback or delay would affect the central thesis that its engine can consistently produce clinically meaningful assets before cash burn and share dilution become harder to justify.
Recursion Pharmaceuticals' current analyst framework points to forecast revenue of US$116.3 million and earnings of US$20.7 million by 2029. That profile assumes revenue grows at 28.5% per year and earnings increase by about US$539.6 million from a loss of US$518.9 million today.
Uncover why Recursion Pharmaceuticals' fair value indicates a 109% potential upside to its current price that could narrow quickly.
Exploring Other Perspectives
One alternative angle focuses less on REC-4881’s progress and more on how bullish analysts already expected Recursion Pharmaceuticals to scale its AI pipeline. Before this news, the most optimistic forecasts were for revenue of about US$382.1 million and earnings of US$65.7 million by 2029, far above consensus. That gap shows how sharply opinions differ and why you may want to compare several narratives yourself.
Explore 6 other Recursion Pharmaceuticals fair value estimates, including one that suggests potential upside of up to 186% from the current price.
The Verdict Is Yours
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider conducting your own research.
- A great starting point for your Recursion Pharmaceuticals research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.
- See our latest analysis for Recursion Pharmaceuticals. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Recursion Pharmaceuticals' overall financial health at a glance.
Looking for more ideas beyond Recursion Pharmaceuticals?
If the Recursion Pharmaceuticals story has you thinking about where else AI, balance sheet strength, or potential mispricing could matter, the Simply Wall St Screener can help you widen your watchlist quickly without drowning you in noise.
- For investors who care most about financial resilience and clean accounts, start with a list of solid balance sheet and fundamentals (25 results) that can help you focus on sturdier businesses first.
- If you want to tilt toward potential upside while still keeping quality in view, consider a 42 high quality undervalued stocks that filters for companies where fundamentals and price appear misaligned.
- For readers who enjoy spotting earlier stage opportunities before they hit the mainstream, there is a 21 high quality undiscovered gems that highlights lesser known stocks with stronger underlying metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com